Pseudomonas aeruginosa as an Opportunistic Pathogen

Provides balanced coverage of epidemiology, pathogenesis, clinical features, and control measures in 19 chapters contributed by authorities on specific aspects of P. aeruginosa research. The volume should prove useful to physicians and surgeons who have in their care patients infested, or at risk of

[1]  I. A. Holder,et al.  Flagellar preparations from Pseudomonas aeruginosa: animal protection studies , 1982, Infection and immunity.

[2]  T. Anderson,et al.  Flagellar antibody stimulated opsonophagocytosis of Pseudomonas aeruginosa associated with response to either a- or b-type flagellar antigen. , 1989, Canadian journal of microbiology.

[3]  T. Montie,et al.  Flagella, motility and invasive virulence of Pseudomonas aeruginosa. , 1988, Journal of general microbiology.

[4]  A. Kreger.  Pathogenesis of Pseudomonas aeruginosa ocular diseases. , 1983, Reviews of Infectious Diseases.

[5]  D. Teres,et al.  Pneumonia in an intensive care unit. A 30-month experience. , 1974, Archives of internal medicine.

[6]  C. Norden,et al.  Experimental osteomyelitis caused by Pseudomonas aeruginosa. , 1980, The Journal of infectious diseases.

[7]  R. Winchurch,et al.  Prophylactic intravenous immunoglobulin replacement in high-risk burn patients. , 1987, The Journal of burn care & rehabilitation.

[8]  J. Mcgowan,et al.  PSEUDOMONAS AERUGINOSA PERITONITIS ASSOCIATED WITH CONTAMINATED POLOXAMER-IODINE SOLUTION , 1982, The Lancet.

[9]  Hughes Jm.  Epidemiology and prevention of nosocomial pneumonia. , 1988 .

[10]  J. Skipper,et al.  Pseudomonas osteochondritis complicating puncture wounds in children. , 1994, Journal of pediatric orthopedics.

[11]  J. Posner,et al.  CENTRAL NERVOUS SYSTEM INFECTIONS IN PATIENTS WITH CANCER , 1973, Medicine.

[12]  A. Kropinski,et al.  Heat shock response of Pseudomonas aeruginosa , 1988, Journal of bacteriology.

[13]  M. Collins,et al.  Protective activity of an intravenous immune globulin (human) enriched in antibody against lipopolysaccharide antigens of Pseudomonas aeruginosa. , 1984, The American journal of medicine.

[14]  M. Tong.  Septic complications of war wounds. , 1972, JAMA.

[15]  B. Piraino,et al.  A five-year study of the microbiologic results of exit site infections and peritonitis in continuous ambulatory peritoneal dialysis. , 1987, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[16]  G. P. Kerby.  Pseudomonas aeruginosa bacteremia; summary of literature, with report of a case. , 1947, American journal of diseases of children.

[17]  H. Chapel,et al.  Crossover study of immunoglobulin replacement therapy in patients with low-grade B-cell tumors. , 1989, Blood.

[18]  E. Jawetz,et al.  Infections of the central nervous system due to pseudomonas aeruginosa. , 1969, Journal of neurosurgery.

[19]  R. Douglas,et al.  Malignant external otitis: a severe form of otitis in diabetic patients. , 1976, The American journal of medicine.

[20]  Y. Masuho,et al.  Characterization of a human monoclonal antibody to lipopolysaccharides of Pseudomonas aeruginosa serotype 5: a possible candidate as an immunotherapeutic agent for infections with P. aeruginosa. , 1985, The Journal of infectious diseases.

[21]  M. Glauser,et al.  Demonstration of cross-reactive antibodies to smooth gram-negative bacteria in antiserum to Escherichia coli J5. , 1987, The Journal of infectious diseases.

[22]  P. Carbone,et al.  Pseudomonas pneumonia. A retrospective study of 36 cases. , 1973, The American journal of medicine.

[23]  J. Gatell,et al.  Pseudomonas aeruginosa bacteremia: univariate and multivariate analyses of factors influencing the prognosis in 133 episodes. , 1988, Reviews of infectious diseases.

[24]  R. Bland,et al.  Otitis media in the first six weeks of life: diagnosis, bacteriology, and management. , 1972, Pediatrics.

[25]  W. Steinmüller,et al.  Pharmacokinetics of anti-Pseudomonas hyperimmunoglobulin after single intravenous administration in healthy subjects , 1989 .

[26]  N. Sigal,et al.  Human monoclonal antibodies that protect mice against challenge with Pseudomonas aeruginosa , 1988, Infection and immunity.

[27]  A. Fanaroff,et al.  Use of intravenously administered immune globulin to prevent nosocomial sepsis in low birth weight infants: report of a pilot study. , 1989, The Journal of pediatrics.

[28]  D. Armstrong,et al.  Bacteremia and fungemia in patients with neoplastic disease. , 1987, The American journal of medicine.

[29]  S. Pitlik,et al.  Ecthyma gangrenosum without bacteremia. Report of six cases and review of the literature. , 1987, Archives of internal medicine.

[30]  R. Quintiliani,et al.  Bacteremic Pseudomonas pneumonia. , 1974, JAMA.

[31]  P. Schmitz,et al.  The influence of immunoglobulin on the development of Pseudomonas aeruginosa infection in an immunocompromised mouse model. , 1985, Journal of biological standardization.

[32]  M. Collins,et al.  Comparative anti-Pseudomonas aeruginosa activity of chemically modified and native immunoglobulin G (human), and potentiation of antibiotic protection against Pseudomonas aeruginosa and group B Streptococcus in vivo. , 1984, The American journal of medicine.

[33]  C. Kallick,et al.  Outbreak of endocarditis caused by Pseudomonas aeruginosa serotype O11 among pentazocine and tripelennamine abusers in Chicago. , 1985, The Journal of infectious diseases.

[34]  D. Kemeny,et al.  IgG subclass antibody production in human serum sickness. , 1990, The Journal of allergy and clinical immunology.

[35]  R. Hodges,et al.  Inhibition of pilus-mediated adhesion of Pseudomonas aeruginosa to human buccal epithelial cells by monoclonal antibodies directed against pili , 1990, Infection and immunity.

[36]  J. Nadol,et al.  Invasive external otitis. Report of 21 cases and review of the literature. , 1981, The American journal of medicine.

[37]  A. Neely,et al.  Plasma proteolytic activity following burns. , 1988, The Journal of trauma.

[38]  N. Sigal,et al.  A human monoclonal antibody that protects mice against Pseudomonas-induced pneumonia. , 1990, The Journal of infectious diseases.

[39]  T. Montie,et al.  Protection against Pseudomonas aeruginosa infection by passive transfer of anti-flagellar serum. , 1987, Canadian journal of microbiology.

[40]  M. McPherson,et al.  The molecular and biochemical basis of cystic fibrosis , 1987, Bioscience reports.

[41]  D. Thornton,et al.  Mucinophilic and chemotactic properties of Pseudomonas aeruginosa in relation to pulmonary colonization in cystic fibrosis , 1990, Infection and immunity.

[42]  V. Yu,et al.  Malignant external otitis: insights into pathogenesis, clinical manifestations, diagnosis, and therapy. , 1988, The American journal of medicine.

[43]  H. Ceri,et al.  Immunochemical examination of the Pseudomonas aeruginosa glycocalyx: a monoclonal antibody which recognizes L-guluronic acid residues of alginic acid. , 1985, Canadian journal of microbiology.

[44]  M. Lederman,et al.  Diagnosis of nosocomial pneumonia in intubated, intensive care unit patients. , 1987, The American review of respiratory disease.

[45]  J. McCutchan,et al.  Treatment of gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coli. , 1983, The New England journal of medicine.

[46]  Y. Masuho,et al.  Protection against infection with Pseudomonas aeruginosa by passive transfer of monoclonal antibodies to lipopolysaccharides and outer membrane proteins. , 1984, The Journal of infectious diseases.

[47]  J. Pennington,et al.  Influence of genetic factors on natural resistance of mice to Pseudomonas aeruginosa. , 1979, The Journal of infectious diseases.

[48]  I. Fong,et al.  Review of Pseudomonas aeruginosa meningitis with special emphasis on treatment with ceftazidime. , 1985, Reviews of infectious diseases.

[49]  A. Nowotny,et al.  Relationship of structure to function in bacterial endotoxins: serologically cross-reactive components and their effect on protection of mice against some gram-negative infections. , 1976, Journal of general microbiology.

[50]  R. Ansorg.  [Flagella specific H antigenic schema of Pseudomonas aeruginosa (author's transl)]. , 1978, Zentralblatt fur Bakteriologie, Parasitenkunde, Infektionskrankheiten und Hygiene. Erste Abteilung Originale. Reihe A: Medizinische Mikrobiologie und Parasitologie.

[51]  R. Ramphal,et al.  Evidence for the in vivo degradation of human respiratory mucins during Pseudomonas aeruginosa infection. , 1989, Biochimica et biophysica acta.

[52]  James R. Chandler.  Malignant external otitis , 1968, The Laryngoscope.

[53]  A. Plebani,et al.  Intravenous gammaglobulin therapy for prophylaxis of infection in high-risk neonates. , 1987, The Journal of pediatrics.

[54]  P. Edmonds,et al.  Epidemiology of pseudomonas aeruginosa in a burn hospital: evaluation of serological, bacteriophage, and pyocin typing methods. , 1972, Applied microbiology.

[55]  H. Levison,et al.  Benefit of intravenous IgG replacement in hypogammaglobulinemic patients with chronic sinopulmonary disease. , 1985, The American journal of medicine.

[56]  J. Pennington,et al.  Passive immune therapy for experimental Pseudomonas aeruginosa pneumonia in the neutropenic host. , 1987, The Journal of infectious diseases.

[57]  L. S. Young,et al.  Functionally active monoclonal antibody that recognizes an epitope on the O side chain of Pseudomonas aeruginosa immunotype-1 lipopolysaccharide , 1986, Infection and immunity.

[58]  Y. Masuho,et al.  A new common polysaccharide antigen of strains of Pseudomonas aeruginosa detected with a monoclonal antibody. , 1985, The Journal of infectious diseases.

[59]  R. Klein,et al.  Wound Infection During the Yom Kippur War; Observations Concerning Antibiotic Prophylaxis and Therapy , 1975, Annals of surgery.

[60]  M. Collins,et al.  Anti-Pseudomonas aeruginosa activity of an intravenous human IgG preparation in burned mice. , 1983, The Journal of trauma.

[61]  J. Naglich,et al.  Experimental studies of the pathogenesis of infections due to Pseudomonas aeruginosa. Treatment with intravenous immune globulin. , 1984, The American journal of medicine.

[62]  B. Chabner,et al.  Pseudomonas blepharoconjunctivitis: a complication of combination chemotherapy. , 1974, Archives of ophthalmology.

[63]  M. Pollack,et al.  Exotoxin production by clinical isolates of pseudomonas aeruginosa , 1977, Infection and immunity.

[64]  M. Campa,et al.  Role of specific delayed-type hypersensitivity in Pseudomonas aeruginosa-infected mice. , 1982, Immunology.

[65]  D. R. Barry,et al.  Postoperative infection with Pseudomonas aeruginosa in an eye hospital. , 1966, Lancet.

[66]  C. Feit,et al.  The presence of viral particles in hybridoma clones secreting monoclonal antibodies. , 1982, The New England journal of medicine.

[67]  P. Gallagher,et al.  Pseudomonas bacteremia in a community teaching hospital, 1980-1984. , 1989, Reviews of infectious diseases.

[68]  A. Arbulu,et al.  Consequences of total tricuspid valvulectomy without prosthetic replacement in treatment of Pseudomonas endocarditis. , 1974, The Journal of thoracic and cardiovascular surgery.

[69]  N. Sigal,et al.  X-linked immunodeficient mice as a model for testing the protective efficacy of monoclonal antibodies against Pseudomonas aeruginosa , 1988, Infection and immunity.

[70]  H. Hill,et al.  Comparative opsonic activity of intravenous gamma globulin preparations for common bacterial pathogens. , 1984, The American journal of medicine.

[71]  J. Alexander,et al.  Clinical evaluation of Pseudomonas hyperimmune globulin. , 1973, The Journal of surgical research.

[72]  T. Kawamura,et al.  Occurrence of D-rhamnan as the common antigen reactive against monoclonal antibody E87 in Pseudomonas aeruginosa IFO 3080 and other strains , 1990, Journal of bacteriology.

[73]  W. Shellow,et al.  Green striped nails: chromonychia due to Pseudomonas aeruginosa. , 1968, Archives of Dermatology.

[74]  A. Mason,et al.  Current approach to prevention and treatment of Pseudomonas aeruginosa infections in burned patients. , 1983, Reviews of infectious diseases.

[75]  P. Liu,et al.  Three new major somatic antigens of Pseudomonas aeruginosa , 1990, Journal of clinical microbiology.

[76]  K. Murakami,et al.  Monoclonal antibodies against species-specific cephalosporinase of Pseudomonas aeruginosa. , 1985, European journal of biochemistry.

[77]  P. Liu,et al.  Exotoxins of Pseudomonas aeruginosa. II. Concentration, purification, and characterization of exotoxin A. , 1973, The Journal of infectious diseases.

[78]  M. Collins,et al.  Opsonic and protective activity of five human IgM monoclonal antibodies reactive with lipopolysaccharide antigen of Pseudomonas aeruginosa. , 1990, FEMS microbiology immunology.

[79]  C. Kallick,et al.  Recovery of Pseudomonas aeruginosa from syringes of drug addicts with endocarditis. , 1981, The Journal of infectious diseases.

[80]  P. Edmonds,et al.  Epidemiology of Pseudomonas aeruginosa in a Burns Hospital: Surveillance by a Combined Typing System , 1972, Applied microbiology.

[81]  E. McGroarty,et al.  Analysis of a common-antigen lipopolysaccharide from Pseudomonas aeruginosa , 1989, Journal of bacteriology.

[82]  D. Woods,et al.  Monoclonal antibodies to Pseudomonas aeruginosa ferripyochelin-binding protein , 1986, Infection and immunity.

[83]  M. Vasil,et al.  Incidence of exotoxin production by Pseudomonas species , 1977, Infection and immunity.

[84]  M. Heckman,et al.  Pseudomonas aeruginosa pneumonia in adults. , 1973, The American review of respiratory disease.

[85]  V. Yu,et al.  Antibiotic therapy for Pseudomonas aeruginosa bacteremia: outcome correlations in a prospective study of 200 patients. , 1989, The American journal of medicine.

[86]  D. Dunn,et al.  Treatment of experimental gram-negative bacterial sepsis with murine monoclonal antibodies directed against lipopolysaccharide. , 1989, Surgery.

[87]  H. Noguchi,et al.  Heterogeneity of the L-rhamnose residue in the outer core of Pseudomonas aeruginosa lipopolysaccharide, characterized by using human monoclonal antibodies , 1989, Infection and immunity.

[88]  L. Cluff,et al.  Pseudomonas bacteremia. Review of 108 cases. , 1976, The American journal of medicine.

[89]  L. Corbeil,et al.  Cross-reactivity of monoclonal antibodies to Escherichia coli J5 with heterologous gram-negative bacteria and extracted lipopolysaccharides. , 1989, The Journal of infectious diseases.

[90]  M. Thomassen,et al.  Flagella and motility alterations in Pseudomonas aeruginosa strains from patients with cystic fibrosis: relationship to patient clinical condition , 1985, Infection and immunity.

[91]  W. R. Mccabe,et al.  Meningitis caused by gram-negative bacilli. , 1980, Annals of internal medicine.

[92]  J. Pennington,et al.  Pseudomonas hyperimmune globulin passive immunotherapy for pulmonary exacerbations in cystic fibrosis , 1990, Pediatric pulmonology.

[93]  G. D. Thomas,et al.  Nosocomial respiratory infections with gram-negative bacilli. The significance of colonization of the respiratory tract. , 1972, Annals of internal medicine.

[94]  G. Pier,et al.  In vitro and in vivo activity of polyclonal and monoclonal human immunoglobulins G, M, and A against Pseudomonas aeruginosa lipopolysaccharide , 1989, Infection and immunity.

[95]  J. McCutchan,et al.  Prevention of lethal pseudomonas bacteremia with epimerase-deficient E. coli antiserum. , 1975, Transactions of the Association of American Physicians.

[96]  S. Davis,et al.  Efficacy of modified human immune serum globulin in the treatment of experimental murine infections with seven immunotypes of Pseudomonas aeruginosa. , 1975, The Journal of infectious diseases.

[97]  R. Lynn,et al.  Pseudomonal and candidal peritonitis as a complication of continuous ambulatory peritoneal dialysis in human immunodeficiency virus-infected patients. , 1989, The American journal of medicine.

[98]  H. Jacot-Guillarmod.  Human Monoclonal Antibodies , 1990 .

[99]  L. Saravolatz,et al.  Safety, pharmacokinetics, and functional activity of human anti-Pseudomonas aeruginosa monoclonal antibodies in septic and nonseptic patients. , 1991, The Journal of infectious diseases.

[100]  B. Greenbaum.  Differences in Immunoglobulin Preparations for Intravenous Use: A Comparison of Six Products , 1990, The American journal of pediatric hematology/oncology.

[101]  E. Honda,et al.  Effects of the common protective antigen (OEP) and toxoids of protease and elastase from Pseudomonas aeruginosa on protection against hemorrhagic pneumonia in mink. , 1977, Zentralblatt fur Bakteriologie, Parasitenkunde, Infektionskrankheiten und Hygiene. Erste Abteilung Originale. Reihe A: Medizinische Mikrobiologie und Parasitologie.

[102]  W. Su,et al.  Ecthyma gangrenosum: report of clinical, histopathologic, and bacteriologic aspects of eight cases. , 1984, Journal of the American Academy of Dermatology.

[103]  P S Cohen,et al.  Infective endocarditis caused by gram-negative bacteria: a review of the literature, 1945-1977. , 1980, Progress in cardiovascular diseases.

[104]  R. Craven,et al.  Flagellar preparations from Pseudomonas aeruginosa: isolation and characterization , 1982, Infection and immunity.

[105]  A. Prince,et al.  Cross-reactivity of Pseudomonas aeruginosa antipilin monoclonal antibodies with heterogeneous strains of P. aeruginosa and Pseudomonas cepacia , 1989, Infection and Immunity.

[106]  G. Pier,et al.  Polyclonal and monoclonal antibody therapy for experimental Pseudomonas aeruginosa pneumonia , 1986, Infection and immunity.

[107]  K. Irie,et al.  A protective human monoclonal antibody directed to the outer core region of Pseudomonas aeruginosa lipopolysaccharide , 1991, Infection and immunity.

[108]  J. G. Foster,et al.  Nosocomial Pseudomonas aeruginosa urinary tract infections. , 1982, JAMA.

[109]  R. J. Jones,et al.  CONTROLLED TRIAL OF PSEUDOMONAS IMMUNOGLOBULIN AND VACCINE IN BURN PATIENTS , 1980, The Lancet.

[110]  G. D. Vermeulen,et al.  Pseudomonas aeruginosa in a center for cancer research. I. Distribution of intraspecies types from human and environmental sources. , 1972, The Journal of infectious diseases.

[111]  D. Armstrong,et al.  Bacteremia due to Pseudomonas aeruginosa complicating neoplastic disease: a progress report. , 1974, The Journal of infectious diseases.

[112]  S. Cryz,et al.  Protection against fatalPseudomonas aeruginosa sepsis by immunization with smooth and rough lipopolysaccharides , 1985, European Journal of Clinical Microbiology.

[113]  W. Steinmüller,et al.  Tolerability and immunogenicity of a polyvalent Pseudomonas aeruginosa extract vaccine in human volunteers. , 1988, Zentralblatt fur Bakteriologie, Mikrobiologie, und Hygiene. Series A, Medical microbiology, infectious diseases, virology, parasitology.

[114]  J. Karp,et al.  Bacterial and host factors affecting Pseudomonas aeruginosa colonization versus bacteremia in granulocytopenic patients. , 1988, European journal of cancer & clinical oncology.

[115]  R. Khabbaz,et al.  Pseudomonas aeruginosa serotype 0:9. New cause of whirlpool-associated dermatitis. , 1983, The American journal of medicine.

[116]  H. Bartsch,et al.  Production of polyclonal and monoclonal antibodies for specific detection of nitrosation-proficient denitrifying bacteria in biological fluids. , 1991, Biochemical and biophysical research communications.

[117]  Y. Suzuki,et al.  Protective effects of S-sulfonated human gamma globulin against experimental infections in mice , 1980, Infection and immunity.

[118]  J. Lagacé,et al.  Four epitopes of Pseudomonas aeruginosa elastase defined by monoclonal antibodies , 1991, Infection and immunity.

[119]  F. Gavini,et al.  Isolation and characterization of monoclonal antibodies against alkaline phosphatase of Pseudomonas aeruginosa , 1989, Journal of clinical microbiology.

[120]  Green Ne,et al.  Pseudomonas infections of the foot after puncture wounds. , 1980 .

[121]  R A Weinstein,et al.  Selective survival in pentazocine and tripelennamine of Pseudomonas aeruginosa serotype O11 from drug addicts. , 1985, The Journal of infectious diseases.

[122]  J. Chia,et al.  Functionally distinct monoclonal antibodies reactive with enzymatically active and binding domains of Pseudomonas aeruginosa toxin A , 1986, Infection and immunity.

[123]  Y. Masuho,et al.  Immunoprotective human monoclonal antibodies against five major serotypes of Pseudomonas aeruginosa. , 1987, Journal of general microbiology.

[124]  J. Wingard,et al.  Antibiotic-resistant bacteria in surveillance stool cultures of patients with prolonged neutropenia , 1986, Antimicrobial Agents and Chemotherapy.

[125]  S. Hadler,et al.  An outbreak of hepatitis A among cancer patients treated with interleukin-2 and lymphokine-activated killer cells. , 1990, The Journal of infectious diseases.

[126]  M. Pollack,et al.  Neutralizing antibody to Pseudomonas aeruginosa exotoxin in human sera: evidence for in vivo toxin production during infection , 1976, Infection and immunity.

[127]  M. Reyes,et al.  Pseudomonas endocarditis in the Detroit Medical Center. 1969-1972. , 1973, Medicine.

[128]  I. Brook,et al.  Bacteriology of chronic otitis media. , 1979, JAMA.

[129]  H. Kaplan,et al.  Protection against gram-negative bacteremia and endotoxemia with human monoclonal IgM antibodies. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[130]  F. Cerra,et al.  Immunotherapy of gram-negative bacterial sepsis. A single murine monoclonal antibody provides cross-genera protection. , 1986, Archives of surgery.

[131]  J. Lundblad,et al.  Comparative studies of impurities in intravenous immunoglobulin preparations. , 1986, Reviews of infectious diseases.

[132]  J. Montgomerie,et al.  Long-term Pseudomonas colonization in spinal cord injury patients. , 1980, American journal of epidemiology.

[133]  A. Lerner,et al.  Characteristics of nonbacteremic Pseudomonas pneumonia. , 1968, Annals of internal medicine.

[134]  K. Yoshida,et al.  Production and some properties of monoclonal antibodies against serotype strains of Pseudomonas aeruginosa. , 1989, Journal of pharmacobio-dynamics.

[135]  D. Levine,et al.  Bacteremia in narcotic addicts at the Detroit Medical Center. II. Infectious endocarditis: a prospective comparative study. , 1986, Reviews of infectious diseases.

[136]  A. Baltch,et al.  Pseudomonas aeruginosa bacteremia: a clinical study of 75 patients , 1977, The American journal of the medical sciences.

[137]  M. Stanley.  Bacillus pyocyaneus infections , 1947 .

[138]  K. Irie,et al.  N-acetyl-L-galactosaminuronic acid as an epitope common to the O-polysaccharides of Pseudomonas aeruginosa serotype A and H (Homma) recognized by a protective human monoclonal antibody. , 1990, European journal of biochemistry.

[139]  J. Whitecar,et al.  Pseudomonas Bacteremia in Patients with Malignant Diseases , 1970, The American journal of the medical sciences.

[140]  T. Calandra,et al.  Antibodies to lipopolysaccharides after immunization of humans with the rough mutant Escherichia coli J5. , 1991, The Journal of infectious diseases.

[141]  Henry Levison,et al.  HIGH-DOSE VERSUS LOW-DOSE INTRAVENOUS IMMUNOGLOBULIN IN HYPOGAMMAGLOBULINAEMIA AND CHRONIC LUNG DISEASE , 1987, The Lancet.

[142]  R. Wilson,et al.  Pulmonary disease associated with Pseudomonas aeruginosa in cystic fibrosis: current status of the host-bacterium interaction. , 1986, The Journal of infectious diseases.

[143]  J. McClain,et al.  Oral ciprofloxacin and a monoclonal antibody to lipopolysaccharide protect leukopenic rats from lethal infection with Pseudomonas aeruginosa. , 1989, The Journal of infectious diseases.

[144]  R. Simmons,et al.  Nosocomial gram-negative bacillary parotitis. , 1984, JAMA.

[145]  Y. Masuho,et al.  Protection against experimental Pseudomonas infection with O antigen-specific human monoclonal antibodies. , 1989, Antibiotics and chemotherapy.

[146]  H. Chapel,et al.  Mechanisms of infection in chronic lymphocytic leukemia. , 1987, Seminars in hematology.

[147]  J. Jacobson,et al.  Pseudomonas aeruginosa rash associated with a whirlpool. , 1976, JAMA.

[148]  R. Hancock,et al.  Monoclonal antibodies provide protection against ocular Pseudomonas aeruginosa infection. , 1988, Investigative ophthalmology & visual science.

[149]  G. Barclay,et al.  Characterisation of mouse monoclonal antibodies produced by immunisation with a single serotype component of a polyvalent Pseudomonas aeruginosa vaccine. , 1986, Journal of medical microbiology.

[150]  J. Alexander,et al.  A prospective trial of prophylactic intravenous immune globulin for the prevention of infections in severely burned patients. , 1989, Burns : journal of the International Society for Burn Injuries.

[151]  M. McPherson,et al.  The biochemical defect in cystic fibrosis. , 1988, Clinical science.

[152]  C. Kunin.  A ten-year study of bacteriuria in schoolgirls: final report of bacteriologic, urologic, and epidemiologic findings. , 1970, The Journal of infectious diseases.

[153]  G. Cooper,et al.  Polymicrobial bacteremia in the late 1980s: predictors of outcome and review of the literature. , 1990, Medicine.

[154]  M. Patzakis,et al.  Septic arthritis due to pseudomonas in heroin addicts. , 1975, The Journal of bone and joint surgery. American volume.

[155]  H. Hill,et al.  Protective and opsonic activities of a native, pH 4.25 intravenous immunoglobulin G preparation against common bacterial pathogens. , 1986, Reviews of infectious diseases.

[156]  M. Grossman,et al.  Subcutaneous nodules in Pseudomonas sepsis. , 1986, The American journal of medicine.

[157]  K. Irie,et al.  Inhibitory activity on bacterial motility and in vivo protective activity of human monoclonal antibodies against flagella of Pseudomonas aeruginosa , 1991, Infection and immunity.

[158]  M. Collins,et al.  Immunoglobulin G: potentiation of tobramycin and azlocillin in the treatment of Pseudomonas aeruginosa sepsis in neutropenic mice and neutralization of exotoxin A in vivo. , 1986, Reviews of infectious diseases.

[159]  D. Armstrong,et al.  Pseudomonas aeruginosa bacteremia in patients with neoplastic disease , 1972, Cancer.

[160]  M. Collins,et al.  Activity of anti-lipopolysaccharide human IgM monoclonal antibodies in the treatment of Pseudomonas aeruginosa-Staphylococcus aureus polymicrobic cellulitis , 1989 .

[161]  L. S. Young,et al.  Enhanced survival in Pseudomonas aeruginosa septicemia associated with high levels of circulating antibody to Escherichia coli endotoxin core. , 1983, The Journal of clinical investigation.

[162]  J. Sugar,et al.  Pseudomonas corneal ulcer with extended-wear soft contact lenses for myopia. , 1983, Archives of ophthalmology.